Mugglehead

Published September 23, 2026

Definium Therapeutics reports 5.1-point gap in second Phase 3 anxiety study - Mugglehead

Read the full story at Mugglehead

CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech. The pivotal agreement is valued at up to US$100 million. Rowan Dunne· Jul.